Cargando…
Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374049/ https://www.ncbi.nlm.nih.gov/pubmed/34421915 http://dx.doi.org/10.3389/fimmu.2021.710110 |
_version_ | 1783740032113180672 |
---|---|
author | Li, Ying Lv, Jiao Shi, Weikai Feng, Jia Liu, Mingxi Gan, Shenao Wu, Hongjin Fan, Weiwei Shi, Ming |
author_facet | Li, Ying Lv, Jiao Shi, Weikai Feng, Jia Liu, Mingxi Gan, Shenao Wu, Hongjin Fan, Weiwei Shi, Ming |
author_sort | Li, Ying |
collection | PubMed |
description | Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that the inflammasome assembly into a higher-order supramolecular complex has been utilized to evaluate the status of the innate immune response. The inflammasomes are now regarded as cellular signaling hubs of the innate immunity that drive the production of inflammatory cytokines and consequent recruitment of immune cells to the tumor sites. Herein, we provided an overview of molecular characteristics and biological properties of canonical and non-canonical inflammasome signaling in cancer immunology and immunotherapy. We also focus on the mechanism of regulating pyroptotic inflammasome in tumor cells, as well as the potential roles of inflammasome-mediated pyroptotic cell death in cancers, to explore the potential diagnostic and therapeutic markers contributing to the prevention and treatment of cancers. |
format | Online Article Text |
id | pubmed-8374049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83740492021-08-20 Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy Li, Ying Lv, Jiao Shi, Weikai Feng, Jia Liu, Mingxi Gan, Shenao Wu, Hongjin Fan, Weiwei Shi, Ming Front Immunol Immunology Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that the inflammasome assembly into a higher-order supramolecular complex has been utilized to evaluate the status of the innate immune response. The inflammasomes are now regarded as cellular signaling hubs of the innate immunity that drive the production of inflammatory cytokines and consequent recruitment of immune cells to the tumor sites. Herein, we provided an overview of molecular characteristics and biological properties of canonical and non-canonical inflammasome signaling in cancer immunology and immunotherapy. We also focus on the mechanism of regulating pyroptotic inflammasome in tumor cells, as well as the potential roles of inflammasome-mediated pyroptotic cell death in cancers, to explore the potential diagnostic and therapeutic markers contributing to the prevention and treatment of cancers. Frontiers Media S.A. 2021-08-05 /pmc/articles/PMC8374049/ /pubmed/34421915 http://dx.doi.org/10.3389/fimmu.2021.710110 Text en Copyright © 2021 Li, Lv, Shi, Feng, Liu, Gan, Wu, Fan and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Ying Lv, Jiao Shi, Weikai Feng, Jia Liu, Mingxi Gan, Shenao Wu, Hongjin Fan, Weiwei Shi, Ming Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title | Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title_full | Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title_fullStr | Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title_full_unstemmed | Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title_short | Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy |
title_sort | inflammasome signaling: a novel paradigm of hub platform in innate immunity for cancer immunology and immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374049/ https://www.ncbi.nlm.nih.gov/pubmed/34421915 http://dx.doi.org/10.3389/fimmu.2021.710110 |
work_keys_str_mv | AT liying inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT lvjiao inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT shiweikai inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT fengjia inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT liumingxi inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT ganshenao inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT wuhongjin inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT fanweiwei inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy AT shiming inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy |